SCHEMBL1941822

SCHEMBL1941822

Cc1ccc(F)cc1S(=O)(=O)Nc1cccc(C(=O)c2cn(C(C)C)c3ncnc(N)c23)c1Cl

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 4/20 0.49
NTRK3 Q16288 2/20 0.49
NTRK2 Q16620 2/20 0.49
PDGFRB P09619 1/20 0.49
EIF2AK3 Q9NZJ5 3/20 0.48
KCNH2 Q12809 2/20 0.47
PDPK1 O15530 8/20 0.43
AKT1 P31749 6/20 0.43
MTOR P42345 6/20 0.43
RET P07949 3/20 0.42
LCK P06239 2/20 0.42
SRC P12931 2/20 0.42
ERN1 O75460 1/20 0.41
AURKA O14965 1/20 0.40
GSK3B P49841 1/20 0.40
MARK1 Q9P0L2 1/20 0.40
SLC16A3 O15427 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1939790 0.92 PDGFRB (0.50) NTRK1NTRK3NTRK2PDGFRBEIF2AK3
SCHEMBL1940442 0.91 EIF2AK3 (0.51) NTRK1NTRK3NTRK2PDGFRBEIF2AK3
SCHEMBL1941746 0.89 PDGFRB (0.50) NTRK1NTRK3NTRK2PDGFRBEIF2AK3
SCHEMBL1941208 0.88 PDGFRB (0.51) NTRK1NTRK3NTRK2PDGFRBEIF2AK3
SCHEMBL1941537 0.88 PDGFRB (0.50) NTRK1NTRK3NTRK2PDGFRBEIF2AK3
SCHEMBL1939650 0.87 PDGFRB (0.51) NTRK1NTRK3NTRK2PDGFRBEIF2AK3
SCHEMBL1941376 0.87 EIF2AK3 (0.51) NTRK1NTRK3NTRK2PDGFRBEIF2AK3
SCHEMBL1939930 0.85 PDGFRB (0.50) NTRK1NTRK3NTRK2PDGFRBEIF2AK3
SCHEMBL1939957 0.85 PDGFRB (0.51) NTRK1NTRK3NTRK2PDGFRBEIF2AK3
SCHEMBL1939941 0.85 PDGFRB (0.55) NTRK1NTRK3NTRK2PDGFRBEIF2AK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578751-B1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PROD INC (US) 2011-06-15 EP disclosed
US-7271262-B2 Pyrrolopyrimidine derivatives PFIZER INC (US) 2007-09-18 US disclosed
CN-1726218-A Pyrrolopyrimidine derivatives PFIZER PROD INC (US) 2006-01-25 CN disclosed
EP-1578751-A1 PYRROLOPYRIMIDINE DERIVATIVES Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20050037999-A1 Pyrrolopyrimidine derivatives PFIZER INC 2005-02-17 US disclosed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037999-A1 Pyrrolopyrimidine derivatives CCNA1, CCNT1, TP53 NTRK1 4135/4885NTRK3 4212/4885NTRK2 4651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.